Oligomerix, Inc. news
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau Oligomers.” The ‘776 patent further strengthens the company’s intellectual property position and coverage for their
- Phase 1 trial of tau-targeting lead program planned to begin in 3Q22
- Funding will also support the characterization of the Company’s second-generation assets
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has recently closed an extension of its Series B funding round, raising $2.7 mill
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer`s Disease (CTAD) conference and at the Society for Neuroscience’s (SfN) 50th annual meeting Neuroscience 2021.
A study was conducted in
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer`s Disease (CTAD) and Society for Neuroscience’s Neuroscience meetings in November 2022.
“With millions of Americans suffering from Alzheimer’s disea
- Award to support Phase 1b studies to evaluate tau self-association small molecule inhibitor
- In August, company announced a $3.35M grant from NIH to support a Phase 1a clinical trial
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $2.49 million from the National Institute on Aging of the National Institutes of
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $3.35 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor. Oligomerix plans to begin a Phase 1a clinical trial in healthy volunteers in 2022.
<- Data presented at AAIC demonstrates oral lead product candidate OLX-07010 reduces tau self-association and insoluble tau aggregates
- Oligomerix to begin clinical testing of OLX-07010 in 2Q22
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company presented at the 2021 Alzheimer`s Association Internati
Appointment of Chief Medical Officer William Erhardt, M.D., to President, Head of Development & Operations
Appointment of Chief Financial Officer Robert Foerster to CFO and Chief Operating Officer
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced several organizational changes reflecting the transition to a clinical-stage pharmaceutica
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced that the company was awarded a $3.19 million grant from the National Institute on Aging (NIA) at National Institutes of Health (NIH). The three-year SBIR/STTR Commercialization Readiness Pilot (CRP) Program award will enable the company to further develop its small molecule tau self-